Last reviewed · How we verify
Halobetasol Proprionate Lotion 0.05%
At a glance
| Generic name | Halobetasol Proprionate Lotion 0.05% |
|---|---|
| Sponsor | Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Halobetasol Proprionate Lotion 0.05% CI brief — competitive landscape report
- Halobetasol Proprionate Lotion 0.05% updates RSS · CI watch RSS
- Therapeutics, Inc. portfolio CI